Adani Enterprises Board Approves ₹25,000 Crore Rights Issue

Adani Enterprises’ Board has approved the issuance of partly paid-up equity shares, raising up to ₹25,000 crore through a rights issue. The decision was made during a board meeting on November 4, 2025. The funds will be raised by offering rights to eligible equity shareholders. The specific terms, including the issue price and record date, will be determined later by the Rights Issue Committee. This move aims to bolster the company’s capital structure for future growth initiatives.

Rights Issue Approval

The Board of Directors of Adani Enterprises has given the green light to a rights issue, allowing the company to raise up to ₹25,000 crore. This decision was formalized during a board meeting held on November 4, 2025, marking a significant step in the company’s financial strategy.

Details of the Issuance

The rights issue will involve the issuance of partly paid-up equity shares, each with a face value of ₹1. These shares will be offered to existing eligible equity shareholders of Adani Enterprises, in accordance with applicable laws and regulations. The specific details regarding the issue price, rights entitlement ratio, record date, and payment terms will be determined subsequently by the authorized Rights Issue Committee and disclosed in due course.

Looking Ahead

The company will disclose the terms of the offering, as required by regulations, in a separate announcement. This move is subject to regulatory and statutory approvals. This rights issue intends to give effect to future projects.

Financial Results for Q2 2026

In addition to the rights issue, the Board also reviewed and approved the unaudited financial results for Q2 2026 (July-September). Some Key highlights of the Unaudited Consolidated financial results are:

  • Total Income: ₹21,844.07 Crores
  • Profit after tax: ₹3,414.43 Crores

Key numbers of the Unaudited Standalone Financial results are :

  • Total Income: ₹5,609.28 Crores
  • Profit after tax: ₹4,234.46 Crores

Source: BSE

Previous Article

Alembic Pharmaceuticals Reports Unaudited Financial Results for Q2 & H1 2026

Next Article

Manappuram Finance Limited Transcript of Q2 FY 2025-26 Results Conference Call

Write a Comment

Leave a Comment

Your email address will not be published. Required fields are marked *